Literature DB >> 15206987

Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.

Ivan Matthews1, Carl Kirkpatrick, Nicholas Holford.   

Abstract

AIMS: [1] To quantify the random and predictable components of variability for aminoglycoside clearance and volume of distribution [2] To investigate models for predicting aminoglycoside clearance in patients with low serum creatinine concentrations [3] To evaluate the predictive performance of initial dosing strategies for achieving an aminoglycoside target concentration.
METHODS: Aminoglycoside demographic, dosing and concentration data were collected from 697 adult patients (> or =20 years old) as part of standard clinical care using a target concentration intervention approach for dose individualization. It was assumed that aminoglycoside clearance had a renal and a nonrenal component, with the renal component being linearly related to predicted creatinine clearance.
RESULTS: A two compartment pharmacokinetic model best described the aminoglycoside data. The addition of weight, age, sex and serum creatinine as covariates reduced the random component of between subject variability (BSVR) in clearance (CL) from 94% to 36% of population parameter variability (PPV). The final pharmacokinetic parameter estimates for the model with the best predictive performance were: CL, 4.7 l h(-1) 70 kg(-1); intercompartmental clearance (CLic), 1 l h(-1) 70 kg(-1); volume of central compartment (V1), 19.5 l 70 kg(-1); volume of peripheral compartment (V2) 11.2 l 70 kg(-1).
CONCLUSIONS: Using a fixed dose of aminoglycoside will achieve 35% of typical patients within 80-125% of a required dose. Covariate guided predictions increase this up to 61%. However, because we have shown that random within subject variability (WSVR) in clearance is less than safe and effective variability (SEV), target concentration intervention can potentially achieve safe and effective doses in 90% of patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206987      PMCID: PMC1884546          DOI: 10.1111/j.1365-2125.2004.02114.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  33 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  The fourth dimension of life: fractal geometry and allometric scaling of organisms.

Authors:  G B West; J H Brown; B J Enquist
Journal:  Science       Date:  1999-06-04       Impact factor: 47.728

3.  Aminoglycoside dosage regimens after therapeutic drug monitoring.

Authors:  Carl M J Kirkpatrick; Evan J Begg; Murray L Barclay; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Plasma creatinine level and creatinine clearance as tests of renal function.

Authors:  K D EDWARDS; H M WHYTE
Journal:  Australas Ann Med       Date:  1959-08

5.  Assessment of the efficacy, safety and quality of gentamicin use in Aberdeen Royal Infirmary.

Authors:  K O Buabeng; A R Mackenzie; R B Laing; I Cook; B Jappy; I M Gould
Journal:  J Antimicrob Chemother       Date:  1999-12       Impact factor: 5.790

6.  Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

Authors:  C M Kirkpatrick; S B Duffull; E J Begg
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

7.  Lysosomal augmentation during aminoglycoside uptake in cochlear hair cells.

Authors:  E Hashino; M Shero; R J Salvi
Journal:  Brain Res       Date:  2000-12-22       Impact factor: 3.252

8.  Evaluation of four once-daily aminoglycoside dosing nomograms.

Authors:  Allison Wood Wallace; Matthew Jones; Joseph S Bertino
Journal:  Pharmacotherapy       Date:  2002-09       Impact factor: 4.705

9.  Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels.

Authors:  Andrew G Bostom; Florian Kronenberg; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2002-08       Impact factor: 10.121

10.  Estimation of glomerular filtration rate in cancer patients.

Authors:  J G Wright; A V Boddy; M Highley; J Fenwick; A McGill; A H Calvert
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

View more
  40 in total

1.  A reduction in between subject variability is not mandatory for selecting a new covariate.

Authors:  Chakradhar V Lagishetty; Pavan Vajjah; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-06       Impact factor: 2.745

2.  Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.

Authors:  Jason A Roberts; Jonathan Field; Adam Visser; Rosemary Whitbread; Mandy Tallot; Jeffrey Lipman; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

4.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

Review 5.  Population clinical pharmacology of children: modelling covariate effects.

Authors:  Brian J Anderson; Karel Allegaert; Nicholas H G Holford
Journal:  Eur J Pediatr       Date:  2006-06-29       Impact factor: 3.183

6.  Assessment of renal function in clinical practice at the bedside of burn patients.

Authors:  J M Conil; B Georges; O Fourcade; T Seguin; M Lavit; K Samii; G Houin; I Tack; S Saivin
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

7.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

Authors:  Stefanie Hennig; Ross Norris; Carl M J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

8.  Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Authors:  Michael A Barras; David Serisier; Stefanie Hennig; Katrina Jess; Ross L G Norris
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

10.  Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Authors:  Vanessa E Rees; Jürgen B Bulitta; Antonio Oliver; Brian T Tsuji; Craig R Rayner; Roger L Nation; Cornelia B Landersdorfer
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.